U.S. Adenomyosis Market Size, Share & Forecast 2026–2032

ID: MR-11404 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: U.S.
  • ✓Market: Adenomyosis Market
  • ✓Market Size 2024: USD 1.18 billion
  • ✓Market Size 2032: USD 2.09 billion
  • ✓CAGR: 7.4%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Off-Label Demand Dominates Prescribing: No FDA-approved adenomyosis indication exists, so prescribers route patients through Orilissa for endometriosis pain and Mirena for heavy menstrual bleeding. AbbVie and Bayer capture adenomyosis revenue without a labeled claim. Sumitomo Pharma's Myfembree follows the same pathway through its heavy-bleeding label.
FINDING 02
Hysterectomy Volumes Will Decline: Conventional wisdom holds that hysterectomy remains the default adenomyosis treatment. Outpatient migration under Medicare's Hospital Outpatient Prospective Payment System, combined with reimbursed MRgFUS delivery in ambulatory settings, will erode that default before 2032.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Payer Coverage Early: Device manufacturers should file an adenomyosis PMA supplement with FDA by December 2026 and pair it with a CMS TCET application. Investors should prioritize evidence-backed MRgFUS platforms before MDUFA VI reauthorization concludes in 2027.

Adenomyosis Care in the United States: Market Overview

The U.S. adenomyosis market generated an estimated USD 1.18 billion in 2024 across branded pharmaceuticals, medical devices, and surgical procedures, based on analyst estimates reconciled against CMS fee schedule volumes and manufacturer disclosures. No therapy carries an FDA-approved adenomyosis indication, so revenue concentrates in adjacent labels: AbbVie's Orilissa for endometriosis pain, Sumitomo Pharma's Myfembree for heavy menstrual bleeding, and Bayer's Mirena for heavy menstrual bleeding.

Government has been the dominant force in shaping how this market is structured. The Centers for Medicare and Medicaid Services sets economics through the Medicare Physician Fee Schedule and the Hospital Outpatient Prospective Payment System, determining whether MRgFUS and uterine-sparing procedures are financially viable. The private sector has led on innovation: InSightec's Exablate system, cleared by FDA for uterine fibroids, and Intuitive Surgical's da Vinci platform have driven procedural adoption wherever payer policy permits.

Policy-Driven Growth in American Adenomyosis Care

Section 2713 of the Public Health Service Act, added by the Patient Protection and Affordable Care Act, requires non-grandfathered private health plans to cover FDA-approved contraceptive methods without cost sharing, following HRSA Women's Preventive Services Guidelines. Levonorgestrel intrauterine systems, including Mirena, qualify, and Mirena's FDA-approved heavy menstrual bleeding indication lets clinicians position it as first-line symptom management for adenomyosis. Zero cost-sharing removes the largest patient barrier, lifting LNG-IUS uptake across commercial and Medicaid populations.

The Centers for Medicare and Medicaid Services' New Technology Add-on Payment program, governed by Section 1886(d)(5)(K) of the Social Security Act, pays hospitals an additional 50 to 65 percent of qualifying device cost for inpatient technologies. The Transitional Coverage for Emerging Technologies pathway, finalized in 2024, extends a parallel route for breakthrough devices. Together these mechanisms reduce hospital capital risk for MRgFUS suites, accelerating installation in academic medical centers and driving procedure volumes.

Regulatory Barriers and Compliance Costs

FDA regulates adenomyosis therapies under the Federal Food, Drug, and Cosmetic Act, and promotion of GnRH antagonists or LNG-IUS for adenomyosis falls outside approved labeling restricted under 21 CFR 202.1. Sponsors pursuing a dedicated indication must run investigational new drug studies under 21 CFR Part 312, while class III ablation devices require premarket approval under 21 CFR Part 814 with an FDA review goal of 180 days under MDUFA V. Pivotal trials for a new adenomyosis label typically cost USD 40 to 80 million and require three to five years.

State certificate-of-need laws administered by state health departments, such as New York's Public Health Law Article 28 review, can delay installation of MRgFUS or outpatient surgical suites by six to 12 months. Hospital Price Transparency rules under 45 CFR Part 180 require posting of negotiated rates, and Open Payments reporting under Section 1128G of the Social Security Act requires manufacturers to disclose physician payments. Compliance adds administrative cost that smaller device firms struggle to absorb.

Policy-Created Opportunities in U.S. Adenomyosis Care

The TCET pathway, capped at five technologies per year, creates a fast route for breakthrough-designated MRgFUS and minimally invasive ablation devices addressing adenomyosis. Manufacturers holding Breakthrough Device designation under Section 515B of the Federal Food, Drug, and Cosmetic Act can apply for TCET coverage once FDA authorization is granted. Hospital systems that install these platforms before the first TCET decisions will capture early referral volume from patients seeking uterine-sparing treatment.

Medicare Drug Price Negotiation under the Inflation Reduction Act creates a defined commercial window for novel oral adenomyosis therapies. Small molecules become eligible for selection seven years after approval, with negotiated prices effective nine years after approval, compared with 11 and 13 years for biologics. Oral GnRH antagonist developers should structure development timelines around that nine-year horizon to protect launch economics.

Regulatory and Policy Environment

The primary legislation governing adenomyosis products is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by the Food and Drug Administration through its Center for Drug Evaluation and Research and Center for Devices and Radiological Health. Medical devices must comply with the Quality Management System Regulation at 21 CFR Part 820, which takes effect February 2, 2026 and aligns U.S. requirements with ISO 13485:2016. Reimbursement falls under Title XVIII of the Social Security Act, administered by CMS, while the Physician Payments Sunshine Act requires manufacturer Open Payments disclosures.

Key upcoming changes include the third Medicare Drug Price Negotiation cycle, with selected drugs announced by February 1, 2026 and negotiated prices effective January 1, 2028, and reauthorization of MDUFA V, which expires September 30, 2027. Compared with the European Union, where Regulation (EU) 2017/745 on medical devices has extended transitional deadlines into 2027 and 2028, the U.S. PMA process offers a defined 180-day review goal but no centralized reimbursement decision. CMS coverage pathways such as TCET attempt to close that gap.

Long-Term Policy Outlook for U.S. Adenomyosis Care

Between 2026 and 2032, MDUFA VI negotiations will determine FDA review resourcing for adenomyosis device submissions, and the QMSR transition will raise audit requirements for smaller manufacturers. The Medicare Drug Price Negotiation Program extends to Part B drugs from 2028, applying to physician-administered GnRH products such as leuprolide, which clinicians use off-label in adenomyosis. Both changes move pricing pressure onto branded hormonal agents.

These changes will reshape the market by shifting revenue from high-priced branded hormonal agents toward lower-cost generics and outpatient procedures. Payers will reward uterine-sparing care that avoids hysterectomy, and CMS payment rules will favor ambulatory MRgFUS delivery. By 2032, the U.S. adenomyosis market should reach USD 2.09 billion as TCET-backed devices and price-negotiated oral therapies capture share.

Market at a Glance

MetricValue
Market Size 2024USD 1.18 billion
Market Size 2032USD 2.09 billion
Growth Rate (CAGR)7.4%
Most Critical Decision FactorPayer coverage of off-label GnRH and hysterectomy alternatives
Largest RegionNortheast
Competitive StructureFragmented; pharmaceutical incumbents and device specialists

Leading Market Participants

  • AbbVie
  • Sumitomo Pharma
  • Bayer
  • Organon
  • InSightec
  • Hologic
  • Intuitive Surgical
  • Johnson & Johnson
  • Medtronic
  • Teva Pharmaceuticals

Frequently Asked Questions

No FDA-approved drug currently carries an adenomyosis indication. Clinicians prescribe Orilissa, Myfembree, and Mirena under their existing labels for related symptoms.
TCET allows CMS to grant coverage for breakthrough devices with FDA marketing authorization before standard coverage decisions are complete. The pathway is capped at five technologies per year.
The Quality Management System Regulation replaces the legacy Quality System Regulation under 21 CFR Part 820 and aligns it with ISO 13485:2016. Manufacturers must comply by February 2, 2026.
Part D covers off-label uses that are supported by compendia citations, such as AHFS-DI or DRUGDEX. Coverage depends on the individual plan's formulary and utilization management rules.
Hospitals must secure any applicable state certificate-of-need approval and comply with CMS outpatient payment and coverage rules. The device itself must hold FDA premarket approval under 21 CFR Part 814.

Market Segmentation

By Treatment Modality
  • Hormonal Therapy
  • Levonorgestrel Intrauterine Systems
  • Uterine-Sparing Procedures
  • Hysterectomy
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Gynecology Clinics
  • Academic Medical Centers
By Payer Type
  • Medicare
  • Medicaid
  • Commercial Insurance
  • Out-of-Pocket

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Adenomyosis Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Treatment Modality Insights
4.1 Hormonal Therapy
4.2 Levonorgestrel Intrauterine Systems
4.3 Uterine-Sparing Procedures
4.4 Hysterectomy
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Gynecology Clinics
5.4 Academic Medical Centers
5.5 Others
Chapter 06 Payer Type Insights
6.1 Medicare
6.2 Medicaid
6.3 Commercial Insurance
6.4 Out-of-Pocket
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 AbbVie
7.2.2 Sumitomo Pharma
7.2.3 Bayer
7.2.4 Organon
7.2.5 InSightec
7.2.6 Hologic
7.2.7 Intuitive Surgical
7.2.8 Johnson & Johnson
7.2.9 Medtronic
7.2.10 Teva Pharmaceuticals
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.